Biomiga Diagnostics Announces Acceptance Into Astia’s Elite Entrepreneur Program and Community

Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced it is joining Astia, a global network serving women-led high growth start-ups.
Nov. 21, 2011 - PRLog -- Biomiga Diagnostics Joins Astia’s Global Network of entrepreneurs, investors, corporations and industry leaders.

Fountain Valley, CA – Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced its invitation to join Astia, the premier global network serving women-led high growth start-ups since 1999.  Biomiga Diagnostics is one of only 31 start-ups joining the elite Astia community for this fall’s Silicon Valley Entrepreneur Program. A hand-picked group of just 224 companies across the globe have been invited to become Astia clients since 2003. Unlike other conferences and programs for entrepreneurs, Astia clients are served by the network, program, and resources throughout the company’s growth.  Invitations are extended only to those companies that pass Astia’s robust screening and qualification process.

The executives of Biomiga Diagnostics are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing.  With more than a decade of drug development experience each, the leadership team has expertise ranging from basic/applied research, preclinical/clinical development, pharmacokinetics/pharmacodynamics biomarker development, regulatory and marketing.

“With each new class of entrepreneurs joining the Astia program, I’m impressed to find these leaders are as talented, innovative and committed to the success of their business as their past peers,” commented Sharon Vosmek, CEO, Astia.  I look forward to working with Biomiga Diagnostics to help accelerate its path to success by teaming them with industry leaders and building valuable connections within the investor community.”

“We are honored to be accepted into Astia’s global community of entrepreneurs and to take part in such a prestigious program,” said Dr. Larn Hwang, Chief Operation Officer of Biomiga Diagnostics. “We are confident that Astia will provide us with the relationships and connections we need to accelerate our company’s growth.  We are impressed with Astia’s line up of experts who are already providing us with valuable business insights to come out on top as a market leader.”

Astia is a global non-profit organization that uniquely sources innovation to exceptional start-ups.  Guided by a proven philosophy that gender diversity is an essential element of innovation, Astia works with start-ups around the world as they access capital, grow their businesses, and hone the leadership skills of their founding teams.  The Astia model of engaging a community of experts to the benefit of the select start-ups it serves has resulted in an exceptional success rate: since 2003, 60 percent of companies that have participated in the Astia Investor Forums have secured funding or achieved an exit within one year of presenting, totaling more than half a billion dollars raised and 17 exits, including two IPOs.  Headquartered in San Francisco, Astia delivers programs for entrepreneurs in Silicon Valley, New York, London and India.  For more information, visit

About Biomiga Diagnostics
Biomiga Diagnostics’ mission is to transform healthcare by quantitative lateral flow tests for Therapeutic Drug Monitoring and biomarker testing.  These tests are simple to use and require no specialized equipment or trained personnel.  They are rapid with results within 20 minutes of blood collection.  They are convenient and can be deployed at home, in doctor’s office, in emergency room, or in centralized laboratory. Moreover, they are quantitative with linear response range similar to tests performed at centralized laboratories.  These proprietary diagnostic devices deployed at point-of-care are the solution to personalized healthcare allowing the dosing of the right patient with the right drug at the right dose.  Biomiga Diagnostics is currently offering two product suites to support the medical community:  1) The Emergency Care suite which includes cardiac biomarkers for heart attack (TnI, CKMB, Myoglobin) and heart failure (BNP). These are the most frequently ordered tests in the emergency rooms. 2) The Reproductive Biology suite which includes the gonadotropins (hCG, LH, FSH). The gonadotropins are widely used in assisted reproduction and their monitoring could improve treatment.  A Chemotherapy Dosing suite including Prostate specific antigen (PSA) is under development.

Larn Hwang

# # #

Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine.
Email:*** Email Verified
Tags:Medical Devices, Startup, Therapeutic Drug Monitoring, Personalized Medicine, Biomarker
Location:Fountain Valley - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share